FindTrial
Sign In

Effect of Gandouling on improving nervous system symptoms of wilson's disease with syndrome of intermingled phlegm and blood stasis

A multicenter randomized controlled double-blind and double-simulated clinical evaluation study of Gandouling in the treatment of patients with wilson's disease with phlegm and blood stasis syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000431
Enrollment
Unknown
Registered
2025-02-27
Start date
2022-12-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wilson's disease

Interventions

healthy control group:none
control group:Dimercaptopropane
treatment group:Gandouling

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine.Anhui Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) It conforms to the diagnostic criteria of western medicine for hepatolenticular degeneration and conforms to the syndrome criteria of phlegm and blood stasis in traditional Chinese medicine. (2) Those who meet the clinical classification of hepatolenticular degeneration. (3)14 years old =60 years old. (4) Patients without standardized copper drainage treatment (5) voluntarily participate or participate with the consent of their guardians and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) The clinical classification of Wilson's disease belongs to patients with liver type. (2) Those with severe mental symptoms can't cooperate with the whole experiment. (3) Complicated with serious organ function damage (such as heart brain kidney spleen and stomach function damage). (4) Pregnant and lactating women. (5) Serious allergic reactions and side effects caused by the use of copper-expelling drugs.

Design outcomes

Primary

MeasureTime frame
DLST;GAS for WD;UWDRS;BI index;TCM syndrome scale score;LIAS;FDX1;DLAT;—

Secondary

MeasureTime frame
CER;ALT;AST;24-hour urine copper;—

Countries

China

Contacts

Public ContactWen-ming Yang

The First Affiliated Hospital of Anhui University of Chinese Medicine.Anhui Province

ywmwyyx@163.com055162838522

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026